Proteomics/Modifier Based on Mass Spectrometry Reveals the Pathogenesis of Eclampsia During Pregnancy and the Screening of Disease Markers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-30

Study Completion Date

2024-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pregnancy-induced hypertension is a unique abnormal blood pressure disease in women during pregnancy, including eclampsia, preeclampsia, pregnancy-induced hypertension, chronic hypertension and so on. Eclampsia can lead to convulsions, proteinuria, multiple organ failure, and eventually death. It is a very serious disease in women, and the incidence of pregnancy-induced hypertension during pregnancy is between 4% and 10%. The incidence of eclampsia ranges from 2% to 5%. Studies have shown that there are about 60,000 cases of stillbirth or stillbirth due to eclampsia every year worldwide. At present, there are many theories about the pathogenesis of eclampsia, such as oxidative stress theory, maternal and fetal interaction theory, immune imbalance theory, heredity theory and so on.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prediction of Preeclampsia by Comprehensive Markers.

NCT03665623

Pre-Eclampsia

COMPLETED

Catestatin and Hypertension in Pregnancy

NCT03200743

Pre-Eclampsia Eclampsia Hypertension, Pregnancy-Induced +1 more

UNKNOWN

Serum LncRNAs as Early Potential Biomarkers for the Prediction of Preeclampsia

NCT03903393

Preeclampsia

UNKNOWN

Investigation of the Serum Mucoprotein 3 (MUC3) Protein Levels in Gestational Hypertensive Disease

NCT04421183

Muc3 Pregnancy Induced Hypertension

COMPLETED

Prediction of Early Pre-eclampsia From Maternal Factors, Biophysical and Biochemical Markers at First Trimester

NCT02990767

Pre-Eclampsia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mechanism Marker Screening

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

The control group

Intervention Type OTHER

Experimental group

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Women with preeclampsia:

1. Singleton women who meet the diagnostic criteria for preeclampsia.
2. No previous history of major disease.
3. Body mass index is between 23-25kg/m2.
4. 20-45 years old.
5. 22-42 weeks of gestation.
6. Participate in the test voluntarily and sign the informed consent.

2\. Healthy pregnant women:
1. In good health, no history of major diseases before pregnancy, pregnant women and single mothers with healthy fetuses (newborn) after pregnancy and delivery.
2. Body mass index is between 23-25kg/m2.
3. 20-45 years old.
4. 22-42 weeks of gestation.
5. Participate in the test voluntarily and sign the informed consent.

Exclusion Criteria

* 1\. Women with preeclampsia:

1. Patients with essential hypertension.
2. Pregnant women with high blood glucose before and/or during pregnancy.
3. Convulsions on the basis of preeclampsia that cannot be explained by other reasons.
4. Women with primary disease due to other non-preeclampsia diseases before and after pregnancy, such as cardiovascular, cerebrovascular, liver, kidney, hematopoietic, endocrine, immune, precancerous lesions or cancers, including the reproductive system.
5. Twin or multiple births.
6. Pregnant women with mental disorders or mental diseases.
7. Using illegal drugs before and after pregnancy.
8. Persons with sexually transmitted diseases or infectious diseases.
9. Pregnant women receiving prenatal steroid therapy.

2\. Healthy pregnant women:
1. Patients with severe maternal and/or fetal (newborn) adverse events during or after the third trimester of pregnancy or delivery. Such as intrauterine infection, amniotic fluid embolism and other serious maternal adverse events; Fetal malformation, fetal growth restriction, fetal intrauterine distress, neonatal hemolysis and other serious fetal (neonatal) adverse events.
2. Pregnant women with other diseases before and after pregnancy, such as cardiovascular and cerebrovascular, liver, kidney, hematopoietic system, endocrine system, immune system, precancerous lesions or cancer, including the reproductive system, and other serious primary diseases.
3. Women with a clear cause of premature delivery.
4. Twin or multiple births.
5. Pregnant women with mental disorders or mental diseases.
6. Use illegal drugs before and after pregnancy.
7. Persons suffering from sexually transmitted diseases or infectious diseases.
8. Pregnant women receiving prenatal steroid therapy.

Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes